It has been about a month since the last earnings report for United Therapeutics (UTHR Quick QuoteUTHR - Free Report) . Shares have lost about 8% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is United Therapeutics due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for United Therapeutics Corporation before we dive into how investors and analysts have reacted as of late.

Q2 Earnings Beat Estimates, Revenues Miss Mark

United Therapeutics reported second-quarter EPS of $7.27, beating the Zacks Consensus Estimate of $6.82. Earnings increased 13.4% year over year.

Revenues in the quarter totaled $783.3 million, which missed the Zacks Consensus Estimate of $803 million. Revenues declined 2% year over year.

Q2 Results in Detail

Combined Tyvaso sales totaled $452.6 million, down 4% year over year due to lower revenues from nebulized Tyvaso. Tyvaso sales fell short of the Zacks Consensus Estimate of $469 million.

Tyvaso DPI generated revenues of $326.6 million, climbing 4% year over year due to an increase in patient demand and some pricing benefits.

Revenues from nebulized Tyvaso (treprostinil) were $126 million, down 18%, largely due to reduced U.S. demand despite modest price increases.

Sales of Orenitram rose 1% year over year to $125.7 million.

Remodulin (including Remunity Pump) sales declined 6% year over year to $126.3 million primarily due to lower demand in the United States despite an increase in international revenues.

Unituxin sales were up 12% year over year to $65.2 million.

Adcirca sales were $6.7 million, roughly consistent with the prior-year quarter.

Research and development expenses were $146.3 million in the quarter, up 9% year over year, mainly due to higher spending on clinical programs and a rise in the fair value of contingent consideration liabilities related to acquired manufactured organ and organ alternative projects.

Selling, general and administrative expenses declined 3% year over year to $206.7 million in the quarter.

As of June 30, 2026, UTHR had cash, cash equivalents and investments of $3.8 billion compared with $3.5 billion as of March 31, 2026.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a downward trend in estimates revision.

The consensus estimate has shifted -7.92% due to these changes.

VGM Scores

Currently, United Therapeutics has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, United Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

United Therapeutics is part of the Zacks Medical - Drugs industry. Over the past month, Corcept Therapeutics (CORT Quick QuoteCORT - Free Report) , a stock from the same industry, has gained 4.5%. The company reported its results for the quarter ended June 2026 more than a month ago.

Corcept reported revenues of $256.15 million in the last reported quarter, representing a year-over-year change of +31.7%. EPS of $0.36 for the same period compares with $0.29 a year ago.

For the current quarter, Corcept is expected to post earnings of $0.58 per share, indicating a change of +262.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.9% over the last 30 days.

Corcept has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.